Identification

Name
Ethosuximide
Accession Number
DB00593  (APRD00318)
Type
Small Molecule
Groups
Approved
Description

An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures. [PubChem]

Structure
Thumb
Synonyms
  • (+-)-2-Ethyl-2-methylsuccinimide
  • (±)-2-ethyl-2-methylsuccinimide
  • 2-ethyl-2-methylsuccinimide
  • 2-Methyl-2-ethylsuccinimide
  • 3-ethyl-3-methyl-2,5-pyrrolidinedione
  • 3-Ethyl-3-methylsuccinimide
  • 3-Methyl-3-ethylpyrrolidine-2,5-dione
  • 3-Methyl-3-ethylsuccinimide
  • Aethosuximide
  • alpha-Ethyl-alpha-methylsuccinimide
  • alpha-Methyl-alpha-ethylsuccinimide
  • Atysmal
  • Ethosuximid
  • Ethosuximide
  • Ethosuximidum
  • Etosuximida
  • gamma-Ethyl-gamma-methyl-succinimide
  • gamma-Methyl-gamma-ethyl-succinimide
  • Thilopemal
  • γ-ethyl-γ-methyl-succinimide
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ZarontinCapsule250 mg/1OralParke Davis Div Of Pfizer Inc2000-09-22Not applicableUs
Zarontin Cap 250mgCapsule250 mgOralErfa Canada 2012 Inc1960-12-31Not applicableCanada
Zarontin Syr 250mg/5mlSyrup250 mgOralErfa Canada 2012 Inc1964-12-31Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
EthosuximideCapsule250 1/1OralZydus Pharmaceuticals Usa, Inc.2012-10-10Not applicableUs
EthosuximideSolution250 mg/5mLOralMikart, Inc.2003-12-22Not applicableUs
EthosuximideSolution250 mg/5mLOralGreenstone, Llc2002-02-27Not applicableUs
EthosuximideCapsule250 mg/1OralAvera Mc Kennan Hospital2015-10-302018-06-09Us
EthosuximideSolution250 mg/5mLOralVersa Pharm Incorporated2004-01-01Not applicableUs
EthosuximideCapsule250 mg/1OralGreenstone, Llc2000-09-22Not applicableUs
EthosuximideCapsule, liquid filled250 mg/1OralBanner Life Sciences Llc.2015-06-01Not applicableUs
EthosuximideSolution250 mg/5mLOralPharmaceutical Associates, Inc.2000-11-22Not applicableUs
EthosuximideCapsule250 mg/1OralPliva, Inc.2002-11-012018-01-26Us50111 0901 01 nlmimage10 8b3245d2
EthosuximideCapsule, liquid filled250 mg/1OralBionpharma Inc.2016-10-21Not applicableUs
International/Other Brands
Emeside (Chemidex) / Ethymal (Apotex Europe) / Etoxin (Apsen) / Petimid (Osel) / Petinimid (Gerot) / Petnidan (Desitin) / Suxilep (Jenapharm) / Suxinutin (McNeil) / Zarondan (Pfizer)
Categories
UNII
5SEH9X1D1D
CAS number
77-67-8
Weight
Average: 141.1677
Monoisotopic: 141.078978601
Chemical Formula
C7H11NO2
InChI Key
HAPOVYFOVVWLRS-UHFFFAOYSA-N
InChI
InChI=1S/C7H11NO2/c1-3-7(2)4-5(9)8-6(7)10/h3-4H2,1-2H3,(H,8,9,10)
IUPAC Name
3-ethyl-3-methylpyrrolidine-2,5-dione
SMILES
CCC1(C)CC(=O)NC1=O

Pharmacology

Indication

For the treatment of petit mal epilepsy.

Associated Conditions
Pharmacodynamics

Used in the treatment of epilepsy. Ethosuximide suppresses the paroxysmal three cycle per second spike and wave activity associated with lapses of consciousness which is common in absence (petit mal) seizures. The frequency of epileptiform attacks is reduced, apparently by depression of the motor cortex and elevation of the threshold of the central nervous system to convulsive stimuli.

Mechanism of action

Binds to T-type voltage sensitive calcium channels. Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1G gives rise to T-type calcium currents. T-type calcium channels belong to the "low-voltage activated (LVA)" group and are strongly blocked by mibefradil. A particularity of this type of channels is an opening at quite negative potentials and a voltage-dependent inactivation. T-type channels serve pacemaking functions in both central neurons and cardiac nodal cells and support calcium signaling in secretory cells and vascular smooth muscle. They may also be involved in the modulation of firing patterns of neurons which is important for information processing as well as in cell growth processes.

TargetActionsOrganism
AVoltage-dependent T-type calcium channel subunit alpha-1G
inhibitor
Human
Absorption

Bioavailability following oral administration is 93%.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Hepatic, via CYP3A4 and CYP2E1.

Route of elimination
Not Available
Half life

53 hours

Clearance
Not Available
Toxicity

Acute overdoses may produce nausea, vomiting, and CNS depression including coma with respiratory depression.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamine2,5-Dimethoxy-4-ethylthioamphetamine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
3-isobutyl-1-methyl-7H-xanthineEthosuximide may increase the excretion rate of 3-isobutyl-1-methyl-7H-xanthine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Illicit
4-MethoxyamphetamineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with 4-Methoxyamphetamine.Experimental, Illicit
5-methoxy-N,N-dimethyltryptamineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with 5-methoxy-N,N-dimethyltryptamine.Experimental, Illicit
6-O-benzylguanineEthosuximide may increase the excretion rate of 6-O-benzylguanine which could result in a lower serum level and potentially a reduction in efficacy.Investigational
7-DeazaguanineEthosuximide may increase the excretion rate of 7-Deazaguanine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
7-NitroindazoleThe risk or severity of adverse effects can be increased when Ethosuximide is combined with 7-Nitroindazole.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
7,9-DimethylguanineEthosuximide may increase the excretion rate of 7,9-Dimethylguanine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
8-azaguanineEthosuximide may increase the excretion rate of 8-azaguanine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
8-chlorotheophyllineEthosuximide may increase the excretion rate of 8-chlorotheophylline which could result in a lower serum level and potentially a reduction in efficacy.Approved
9-DeazaguanineEthosuximide may increase the excretion rate of 9-Deazaguanine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
9-MethylguanineEthosuximide may increase the excretion rate of 9-Methylguanine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
AbafunginThe therapeutic efficacy of Abafungin can be increased when used in combination with Ethosuximide.Investigational
AcefyllineEthosuximide may increase the excretion rate of Acefylline which could result in a lower serum level and potentially a reduction in efficacy.Experimental
AcepromazineThe risk or severity of hypotension can be increased when Acepromazine is combined with Ethosuximide.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Aceprometazine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Acetazolamide.Approved, Vet Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Acetophenazine.Approved
Acetylglycinamide chloral hydrateThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Acetylglycinamide chloral hydrate.Experimental
AcyclovirEthosuximide may increase the excretion rate of Acyclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved
AdinazolamThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Adinazolam.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Alaproclate.Experimental
AlbaconazoleThe therapeutic efficacy of Albaconazole can be increased when used in combination with Ethosuximide.Investigational
AlcuroniumEthosuximide may increase the neuromuscular blocking activities of Alcuronium.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Ethosuximide.Approved, Illicit
AlfuzosinThe risk or severity of hypotension can be increased when Alfuzosin is combined with Ethosuximide.Approved, Investigational
AlimemazineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Alimemazine.Approved, Vet Approved
AllobarbitalThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Allobarbital.Experimental
AllopregnanoloneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Allopregnanolone.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Almotriptan.Approved, Investigational
AlosetronThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Alosetron.Approved, Withdrawn
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ethosuximide.Approved, Illicit, Investigational
AlprenololThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Alprenolol.Approved, Withdrawn
AlverineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Alverine.Approved, Investigational
AmikacinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Amikacin.Approved, Investigational, Vet Approved
AmineptineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Amineptine.Illicit, Withdrawn
AmiodaroneThe metabolism of Ethosuximide can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of hypotension can be increased when Amitriptyline is combined with Ethosuximide.Approved
AmitriptylinoxideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Amitriptylinoxide.Approved, Investigational
AmobarbitalThe metabolism of Ethosuximide can be increased when combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of hypotension can be increased when Amoxapine is combined with Ethosuximide.Approved
AmperozideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Amperozide.Experimental
AmphetamineAmphetamine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Illicit, Investigational
Amphotericin BEthosuximide may decrease the nephrotoxic activities of Amphotericin B.Approved, Investigational
AmprenavirThe metabolism of Ethosuximide can be decreased when combined with Amprenavir.Approved, Investigational
AniracetamThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Aniracetam.Experimental
ApalutamideThe serum concentration of Ethosuximide can be decreased when it is combined with Apalutamide.Approved, Investigational
APD791The risk or severity of adverse effects can be increased when Ethosuximide is combined with APD791.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Apomorphine.Approved, Investigational
ApramycinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Apramycin.Experimental, Vet Approved
AprepitantThe serum concentration of Ethosuximide can be increased when it is combined with Aprepitant.Approved, Investigational
AprobarbitalThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Aprobarbital.Approved, Illicit
ApronalideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Apronalide.Experimental
Arbaclofen PlacarbilThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Arbaclofen Placarbil.Investigational
ArbekacinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Arbekacin.Approved, Investigational
AripiprazoleThe risk or severity of hypotension can be increased when Aripiprazole is combined with Ethosuximide.Approved, Investigational
Aripiprazole lauroxilThe risk or severity of hypotension can be increased when Aripiprazole lauroxil is combined with Ethosuximide.Approved, Investigational
ArotinololThe risk or severity of hypotension can be increased when Arotinolol is combined with Ethosuximide.Investigational
AsenapineThe risk or severity of hypotension can be increased when Asenapine is combined with Ethosuximide.Approved
AtazanavirThe metabolism of Ethosuximide can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Atomoxetine.Approved
AtracuriumEthosuximide may increase the neuromuscular blocking activities of Atracurium.Approved, Experimental, Investigational
Atracurium besylateEthosuximide may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Azaperone.Investigational, Vet Approved
AzathioprineEthosuximide may increase the excretion rate of Azathioprine which could result in a lower serum level and potentially a reduction in efficacy.Approved
AZD-3043The risk or severity of adverse effects can be increased when Ethosuximide is combined with AZD-3043.Investigational
AzelastineEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Ethosuximide.Approved
BamifyllineEthosuximide may increase the excretion rate of Bamifylline which could result in a lower serum level and potentially a reduction in efficacy.Experimental
BarbexacloneThe metabolism of Ethosuximide can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Ethosuximide can be increased when combined with Barbital.Illicit
BeclamideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Beclamide.Experimental
BekanamycinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Bekanamycin.Experimental
BenactyzineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Benactyzine.Withdrawn
BenmoxinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Benperidol.Approved, Investigational
BenzoctamineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Benzoctamine.Approved
BenzphetamineBenzphetamine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Benzyl alcohol.Approved
BevantololThe risk or severity of hypotension can be increased when Bevantolol is combined with Ethosuximide.Approved
BifemelaneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Bifemelane.Experimental
BifeprunoxThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Bifeprunox.Investigational
BifonazoleThe therapeutic efficacy of Bifonazole can be increased when used in combination with Ethosuximide.Approved, Investigational
BisacodylThe therapeutic efficacy of Bisacodyl can be decreased when used in combination with Ethosuximide.Approved
BisoxatinThe therapeutic efficacy of Bisoxatin can be decreased when used in combination with Ethosuximide.Approved
BL-1020The risk or severity of adverse effects can be increased when Ethosuximide is combined with BL-1020.Investigational
BlonanserinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Blonanserin.Approved, Investigational
BoceprevirThe metabolism of Ethosuximide can be decreased when combined with Boceprevir.Approved, Withdrawn
BosentanThe serum concentration of Ethosuximide can be decreased when it is combined with Bosentan.Approved, Investigational
Botulinum Toxin Type AThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Botulinum Toxin Type B.Approved, Investigational
BrexpiprazoleThe risk or severity of hypotension can be increased when Brexpiprazole is combined with Ethosuximide.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.Approved
BrivaracetamThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Brivaracetam.Approved, Investigational
BrofaromineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Brofaromine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Ethosuximide.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Bromisoval.Experimental
BromocriptineThe risk or severity of hypotension can be increased when Bromocriptine is combined with Ethosuximide.Approved, Investigational
BromotheophyllineEthosuximide may increase the excretion rate of Bromotheophylline which could result in a lower serum level and potentially a reduction in efficacy.Approved
BromperidolThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Brotizolam.Approved, Investigational, Withdrawn
BucindololThe risk or severity of hypotension can be increased when Bucindolol is combined with Ethosuximide.Investigational
BufotenineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Bufotenine.Experimental, Illicit
BufyllineEthosuximide may increase the excretion rate of Bufylline which could result in a lower serum level and potentially a reduction in efficacy.Experimental
BunazosinThe risk or severity of hypotension can be increased when Bunazosin is combined with Ethosuximide.Investigational
BuprenorphineEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Ethosuximide.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ethosuximide.Approved, Illicit
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Ethosuximide.Approved, Illicit
ButaperazineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Butaperazine.Experimental
ButethalThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Butethal.Approved, Illicit
ButoconazoleThe therapeutic efficacy of Butoconazole can be increased when used in combination with Ethosuximide.Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Ethosuximide.Approved, Illicit, Vet Approved
ButriptylineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Butriptyline.Approved
CabergolineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Cabergoline.Approved
CafedrineEthosuximide may increase the excretion rate of Cafedrine which could result in a lower serum level and potentially a reduction in efficacy.Investigational
CaffeineEthosuximide may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.Approved
Calcium AcetateThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Calcium Acetate.Approved, Investigational
Calcium CarbonateThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
Calcium ChlorideThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Calcium lactate.Approved, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium levulinateThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Calcium levulinate.Approved, Experimental
Calcium pangamateThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Calcium Phosphate.Approved
CamazepamThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Camazepam.Approved, Illicit
CannabidiolThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Cannabidiol.Approved, Investigational
CannabidivarinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Cannabidivarin.Investigational
CapreomycinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Capreomycin.Approved
CaptodiameThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Captodiame.Approved, Investigational
CarbamazepineThe metabolism of Ethosuximide can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Carbinoxamine.Approved
CarboxymethylcelluloseThe therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Ethosuximide.Approved, Investigational
CarbromalThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Carbromal.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Carfentanil.Illicit, Investigational, Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Cariprazine.Approved, Investigational
CarisbamateThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Carisbamate.Investigational
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Ethosuximide.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Caroxazone.Withdrawn
CarvedilolThe risk or severity of hypotension can be increased when Carvedilol is combined with Ethosuximide.Approved, Investigational
Castor oilThe therapeutic efficacy of Castor oil can be decreased when used in combination with Ethosuximide.Approved, Investigational, Nutraceutical, Vet Approved
CathinoneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Cathinone.Illicit
CeritinibThe serum concentration of Ethosuximide can be increased when it is combined with Ceritinib.Approved
CerlapirdineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Cerlapirdine.Investigational
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Ethosuximide.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Ethosuximide.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroquineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Chlorphenamine.Approved
ChlorphenesinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorphentermineChlorphentermine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.Illicit, Withdrawn
ChlorproethazineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Chlorproethazine.Experimental
ChlorpromazineThe risk or severity of hypotension can be increased when Chlorpromazine is combined with Ethosuximide.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlortetracyclineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Chlortetracycline.Approved, Investigational, Vet Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Ethosuximide.Approved
CilansetronThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Cilansetron.Investigational
CimetidineThe serum concentration of Ethosuximide can be increased when it is combined with Cimetidine.Approved, Investigational
CinitaprideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Cinitapride.Approved, Investigational
CinolazepamThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Cinolazepam.Approved
CisaprideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Cisapride.Approved, Investigational, Withdrawn
CisatracuriumEthosuximide may increase the neuromuscular blocking activities of Cisatracurium.Approved
CitalopramThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Citalopram.Approved
ClarithromycinThe metabolism of Ethosuximide can be decreased when combined with Clarithromycin.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Ethosuximide.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Clidinium.Approved
ClindamycinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Clindamycin.Approved, Vet Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Ethosuximide.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Ethosuximide is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Clomipramine.Approved, Investigational, Vet Approved
ClomocyclineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Clomocycline.Approved
ClonazepamThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Ethosuximide.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Clopenthixol.Experimental
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Ethosuximide.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ethosuximide.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Clothiapine.Experimental
ClotiazepamThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Clotiazepam.Approved, Illicit
ClotrimazoleThe metabolism of Ethosuximide can be decreased when combined with Clotrimazole.Approved, Vet Approved
CloxazolamThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Cloxazolam.Approved, Investigational
ClozapineThe risk or severity of hypotension can be increased when Clozapine is combined with Ethosuximide.Approved
CobicistatThe serum concentration of Ethosuximide can be increased when it is combined with Cobicistat.Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Ethosuximide.Approved, Illicit
ColistimethateThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Colistimethate.Approved, Vet Approved
ColistinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Colistin.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Ethosuximide.Approved, Investigational
CrizotinibThe metabolism of Ethosuximide can be decreased when combined with Crizotinib.Approved
CurcuminThe metabolism of Ethosuximide can be decreased when combined with Curcumin.Approved, Investigational
CyamemazineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Cyamemazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Cyclizine.Approved
CyclobarbitalThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Cyclobarbital.Experimental
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ethosuximide.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Cyclopropane.Experimental
CyclosporineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Ethosuximide.Approved
DabrafenibThe serum concentration of Ethosuximide can be decreased when it is combined with Dabrafenib.Approved, Investigational
DanazolThe metabolism of Ethosuximide can be decreased when combined with Danazol.Approved
DanthronThe therapeutic efficacy of Danthron can be decreased when used in combination with Ethosuximide.Approved, Investigational, Withdrawn
DantroleneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Dantrolene.Approved, Investigational
DapiprazoleThe risk or severity of hypotension can be increased when Dapiprazole is combined with Ethosuximide.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Dapoxetine.Investigational
DarunavirThe metabolism of Ethosuximide can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Ethosuximide can be increased when it is combined with Dasatinib.Approved, Investigational
DeanolThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Deanol.Experimental
DecamethoniumThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Decamethonium.Approved
DeferasiroxThe serum concentration of Ethosuximide can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Ethosuximide can be decreased when combined with Delavirdine.Approved
DelorazepamThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Delorazepam.Approved, Illicit, Investigational
DemeclocyclineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Demeclocycline.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Ethosuximide.Approved
DesipramineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Desipramine.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Ethosuximide can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ethosuximide.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Dexmethylphenidate.Approved, Investigational
DextofisopamThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Dextofisopam.Investigational
DextroamphetamineDextroamphetamine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Ethosuximide.Approved, Illicit, Investigational, Vet Approved
DibekacinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Dibekacin.Experimental
DibenzepinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Dibenzepin.Experimental
DichloralphenazoneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Dichloralphenazone.Approved, Illicit
Diethyl etherThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Diethyl ether.Experimental
DiethylpropionDiethylpropion can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ethosuximide.Approved, Illicit
DihydroergotamineThe risk or severity of hypotension can be increased when Dihydroergotamine is combined with Ethosuximide.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Dihydromorphine.Experimental, Illicit
DihydrostreptomycinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Dihydrostreptomycin.Investigational, Vet Approved
DiltiazemThe metabolism of Ethosuximide can be decreased when combined with Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Dimenhydrinate.Approved
DimetacrineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Dimetacrine.Approved, Withdrawn
DimethyltryptamineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Dimethyltryptamine.Experimental, Illicit
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ethosuximide.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ethosuximide.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Dixyrazine.Experimental
DocusateThe therapeutic efficacy of Docusate can be decreased when used in combination with Ethosuximide.Approved
DolasetronThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Dolasetron.Approved, Investigational
Domoic AcidThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Domoic Acid.Experimental
DonepezilThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Donepezil.Approved
DopamineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Dopamine.Approved
DoramectinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Doramectin.Vet Approved
DosulepinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Dosulepin.Approved
DotarizineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Dotarizine.Investigational
DoxacuriumEthosuximide may increase the neuromuscular blocking activities of Doxacurium.Approved
DoxazosinThe risk or severity of hypotension can be increased when Doxazosin is combined with Ethosuximide.Approved
DoxefazepamThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Doxefazepam.Experimental
DoxepinThe risk or severity of hypotension can be increased when Doxepin is combined with Ethosuximide.Approved, Investigational
DoxofyllineEthosuximide may increase the excretion rate of Doxofylline which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
DoxycyclineThe metabolism of Ethosuximide can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Ethosuximide is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.Approved, Illicit
DronedaroneThe risk or severity of hypotension can be increased when Dronedarone is combined with Ethosuximide.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Dyclonine.Approved
EconazoleThe therapeutic efficacy of Econazole can be increased when used in combination with Ethosuximide.Approved
EcopipamThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Ecopipam.Investigational
EdivoxetineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Edivoxetine.Investigational
EfavirenzThe serum concentration of Ethosuximide can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe therapeutic efficacy of Efinaconazole can be increased when used in combination with Ethosuximide.Approved
EletriptanThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Eletriptan.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Eltanolone.Investigational
EltoprazineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Eltoprazine.Investigational
EmeproniumThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Emepronium.Experimental
EmylcamateThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Emylcamate.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Ethosuximide.Approved, Investigational
EntecavirEthosuximide may increase the excretion rate of Entecavir which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
EnzalutamideThe serum concentration of Ethosuximide can be decreased when it is combined with Enzalutamide.Approved
EperisoneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Eperisone.Approved, Investigational
EpinastineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Epinastine.Approved, Investigational
EplivanserinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Eplivanserin.Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Ergonovine.Approved
ErgotamineThe risk or severity of hypotension can be increased when Ergotamine is combined with Ethosuximide.Approved
ErythromycinThe metabolism of Ethosuximide can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Esmirtazapine.Investigational
EsreboxetineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Esreboxetine.Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Ethosuximide.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Ethosuximide.Approved, Investigational
Etacrynic acidThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Etacrynic acid.Approved, Investigational
EtamiphyllineEthosuximide may increase the excretion rate of Etamiphylline which could result in a lower serum level and potentially a reduction in efficacy.Experimental
EthadioneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Ethadione.Experimental
EthanolEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthotoinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Ethylmorphine.Approved, Illicit
EtifoxineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Etifoxine.Investigational, Withdrawn
EtiracetamThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Etiracetam.Investigational
EtizolamThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Ethosuximide can be decreased when it is combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Ezogabine.Approved, Investigational
FabomotizoleThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Fabomotizole.Experimental
Fazadinium bromideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Fazadinium bromide.Experimental
FebarbamateThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Febarbamate.Experimental
FelbamateThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenethyllineEthosuximide may increase the excretion rate of Fenethylline which could result in a lower serum level and potentially a reduction in efficacy.Approved
FenfluramineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Fenfluramine.Approved, Illicit, Investigational, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ethosuximide.Approved, Illicit, Investigational, Vet Approved
FenticonazoleThe therapeutic efficacy of Fenticonazole can be increased when used in combination with Ethosuximide.Experimental
FenyramidolThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Fenyramidol.Experimental
FexofenadineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Fexofenadine.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Flibanserin.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Fluanisone.Experimental
FluconazoleThe metabolism of Ethosuximide can be decreased when combined with Fluconazole.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of hypotension can be increased when Flupentixol is combined with Ethosuximide.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Ethosuximide.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Ethosuximide.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Ethosuximide.Approved
FlutrimazoleThe therapeutic efficacy of Flutrimazole can be increased when used in combination with Ethosuximide.Experimental
FluvoxamineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Ethosuximide can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Ethosuximide can be increased when it is combined with Fosaprepitant.Approved
FospropofolThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Fospropofol.Approved, Illicit, Investigational
FramycetinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Framycetin.Approved
FrovatriptanThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Frovatriptan.Approved, Investigational
FurafyllineEthosuximide may increase the excretion rate of Furafylline which could result in a lower serum level and potentially a reduction in efficacy.Experimental
FurazolidoneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Furazolidone.Approved, Investigational, Vet Approved
Fusidic AcidThe serum concentration of Ethosuximide can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ethosuximide.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Gabapentin Enacarbil.Approved, Investigational
GaboxadolThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Gaboxadol.Investigational
GallamineEthosuximide may increase the neuromuscular blocking activities of Gallamine.Experimental
Gallamine TriethiodideEthosuximide may increase the neuromuscular blocking activities of Gallamine Triethiodide.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Ethosuximide.Approved, Illicit, Investigational
GanciclovirEthosuximide may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
Gantacurium ChlorideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Gantacurium Chloride.Investigational
GedocarnilThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Gedocarnil.Experimental
GeneticinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Geneticin.Experimental
GentamicinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Gentamicin.Approved, Vet Approved
GENTAMICIN C1AThe risk or severity of adverse effects can be increased when Ethosuximide is combined with GENTAMICIN C1A.Experimental
GepefrineGepefrine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
GepironeThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Glutethimide.Approved, Illicit
GlycerinThe therapeutic efficacy of Glycerin can be decreased when used in combination with Ethosuximide.Approved, Investigational
GranisetronThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Granisetron.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Guanfacine.Approved, Investigational
GuanineEthosuximide may increase the excretion rate of Guanine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
HalazepamThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Ethosuximide.Approved
HalothaneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Halothane.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Harmaline.Experimental
HeptabarbitalThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Heptabarbital.Approved
HeroinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Heroin.Approved, Illicit, Investigational
HexafluroniumThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Hexafluronium.Approved
HexamethoniumThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Hexamethonium.Experimental
HexapropymateThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Hexapropymate.Experimental
HexobarbitalThe metabolism of Ethosuximide can be increased when combined with Hexobarbital.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Hydracarbazine.Experimental
HydrocodoneEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ethosuximide.Approved, Illicit
HydroxyamphetamineHydroxyamphetamine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.Approved
Hygromycin BThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Hygromycin B.Vet Approved
HypericinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Hypericin.Investigational
HypoxanthineEthosuximide may increase the excretion rate of Hypoxanthine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
IdalopirdineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Idalopirdine.Investigational
IdelalisibThe metabolism of Ethosuximide can be decreased when combined with Idelalisib.Approved
IfenprodilThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Ifenprodil.Approved, Investigational, Withdrawn
IferanserinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Iferanserin.Investigational
IloperidoneThe risk or severity of hypotension can be increased when Iloperidone is combined with Ethosuximide.Approved
ImagabalinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Imagabalin.Investigational
ImatinibThe metabolism of Ethosuximide can be decreased when combined with Imatinib.Approved
ImipramineThe risk or severity of hypotension can be increased when Imipramine is combined with Ethosuximide.Approved
Imipramine oxideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Imipramine oxide.Experimental
IndalpineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Ethosuximide can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Indiplon.Investigational
IndoraminThe risk or severity of hypotension can be increased when Indoramin is combined with Ethosuximide.Withdrawn
Iofetamine I-123Iofetamine I-123 can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IprazochromeThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Iprazochrome.Experimental
IprindoleThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Iprindole.Experimental
IproclozideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Iproclozide.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Iproniazid.Withdrawn
IsavuconazoleThe serum concentration of Ethosuximide can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Ethosuximide can be decreased when combined with Isavuconazonium.Approved, Investigational
IsepamicinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Isepamicin.Experimental
IsocarboxazidThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Isocarboxazid.Approved
IsoconazoleThe therapeutic efficacy of Isoconazole can be increased when used in combination with Ethosuximide.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Ethosuximide.Approved, Vet Approved
IsoniazidThe metabolism of Ethosuximide can be decreased when combined with Isoniazid.Approved, Investigational
ItraconazoleThe metabolism of Ethosuximide can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Ethosuximide can be increased when it is combined with Ivacaftor.Approved
KanamycinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Kanamycin.Approved, Investigational, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Ethosuximide.Approved, Vet Approved
KetanserinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Ketanserin.Investigational
KetazolamThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe metabolism of Ethosuximide can be decreased when combined with Ketoconazole.Approved, Investigational
L-TryptophanThe risk or severity of adverse effects can be increased when Ethosuximide is combined with L-Tryptophan.Approved, Nutraceutical, Withdrawn
LabetalolThe risk or severity of hypotension can be increased when Labetalol is combined with Ethosuximide.Approved
LacosamideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Lacosamide.Approved
LactitolThe therapeutic efficacy of Lactitol can be decreased when used in combination with Ethosuximide.Investigational
LactuloseThe therapeutic efficacy of Lactulose can be decreased when used in combination with Ethosuximide.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Ethosuximide.Approved, Investigational
LanicemineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Lanicemine.Investigational
LasmiditanThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Lasmiditan.Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Levetiracetam.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ethosuximide.Approved
LinaclotideThe therapeutic efficacy of Linaclotide can be decreased when used in combination with Ethosuximide.Approved
LincomycinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Lincomycin.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Linezolid.Approved, Investigational
LisdexamfetamineLisdexamfetamine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LisofyllineEthosuximide may increase the excretion rate of Lisofylline which could result in a lower serum level and potentially a reduction in efficacy.Investigational
LisurideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Lisuride.Approved, Investigational
Lithium carbonateThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Lithium carbonate.Approved
Lithium cationThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Lithium cation.Experimental
LobucavirEthosuximide may increase the excretion rate of Lobucavir which could result in a lower serum level and potentially a reduction in efficacy.Investigational
LofentanilThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Lofentanil.Illicit
LofepramineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Lofepramine.Experimental
LofexidineThe therapeutic efficacy of Ethosuximide can be increased when used in combination with Lofexidine.Approved, Investigational
LopinavirThe metabolism of Ethosuximide can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Ethosuximide.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Ethosuximide.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Lormetazepam.Approved
LorpiprazoleThe serum concentration of Ethosuximide can be increased when it is combined with Lorpiprazole.Approved
LortalamineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Lortalamine.Experimental
LovastatinThe metabolism of Ethosuximide can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Ethosuximide.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Ethosuximide.Approved, Investigational
LuliconazoleThe serum concentration of Ethosuximide can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Ethosuximide can be increased when combined with Lumacaftor.Approved
LumateperoneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Lumateperone.Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Ethosuximide.Approved, Investigational
LymecyclineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Lymecycline.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Lysergic Acid Diethylamide.Illicit, Investigational, Withdrawn
m-ChlorophenylpiperazineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with m-Chlorophenylpiperazine.Investigational
Magnesium acetateThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Magnesium acetate.Approved
Magnesium acetate tetrahydrateThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Magnesium acetate tetrahydrate.Approved
Magnesium Aluminum SilicateThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Magnesium Aluminum Silicate.Approved
Magnesium aspartateThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Magnesium aspartate.Experimental
Magnesium carbonateThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Magnesium carbonate.Approved, Investigational
Magnesium cationThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Magnesium cation.Approved, Nutraceutical
Magnesium chlorideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Magnesium chloride.Approved
Magnesium citrateThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Magnesium citrate.Approved
Magnesium gluconateThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Magnesium gluconate.Approved, Investigational
Magnesium glycinateThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Magnesium glycinate.Approved
Magnesium hydroxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Ethosuximide is combined with Magnesium hydroxide.Approved, Investigational
Magnesium orotateThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Magnesium orotate.Experimental
Magnesium oxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Ethosuximide is combined with Magnesium oxide.Approved
Magnesium peroxideThe therapeutic efficacy of Magnesium peroxide can be decreased when used in combination with Ethosuximide.Experimental
Magnesium phosphateThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Magnesium phosphate.Experimental
Magnesium salicylateThe risk or severity of hypotension and neuromuscular blockade can be increased when Ethosuximide is combined with Magnesium salicylate.Approved
Magnesium silicateThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Magnesium silicate.Approved
Magnesium stearateThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Magnesium stearate.Investigational
Magnesium sulfateThe therapeutic efficacy of Ethosuximide can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Magnesium Trisilicate.Approved
MannitolThe therapeutic efficacy of Mannitol can be decreased when used in combination with Ethosuximide.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Maprotiline.Approved, Investigational
MazindolThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Mazindol.Approved, Investigational
MebanazineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Mebanazine.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Mebicar.Experimental
MebutamateThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Mebutamate.Approved
MecamylamineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Mecamylamine.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Medetomidine.Vet Approved
MedifoxamineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Medifoxamine.Experimental
MefloquineThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Mefloquine.Approved, Investigational
MelatoninThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelitracenThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Melitracen.Experimental, Investigational
MelperoneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Melperone.Approved, Investigational
MephedroneMephedrone can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
MephenesinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Mephenesin.Approved
MephenoxaloneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Mephenoxalone.Experimental
MephentermineMephentermine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MephenytoinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Mephenytoin.Investigational, Withdrawn
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ethosuximide.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Mesoridazine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Metaxalone.Approved
MetergolineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Metergoline.Experimental
MethacyclineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Methacycline.Approved, Investigational
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Ethosuximide.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineMethamphetamine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Methaqualone.Illicit, Withdrawn
MetharbitalThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Metharbital.Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Ethosuximide.Approved, Vet Approved
MethohexitalThe metabolism of Ethosuximide can be increased when combined with Methohexital.Approved
MethotrimeprazineEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethoxyphenamineMethoxyphenamine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Methsuximide.Approved
Methyl celluloseThe therapeutic efficacy of Methyl cellulose can be decreased when used in combination with Ethosuximide.Approved
Methylene blueThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Methylene blue.Approved, Investigational
MethylpentynolThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Methylpentynol.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe metabolism of Ethosuximide can be increased when combined with Methylphenobarbital.Approved
MethyprylonThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Methyprylon.Approved, Illicit, Withdrawn
MethysergideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Methysergide.Approved
MetocurineEthosuximide may increase the neuromuscular blocking activities of Metocurine.Approved
Metocurine IodideEthosuximide may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Withdrawn
MetyrosineEthosuximide may increase the sedative activities of Metyrosine.Approved
MianserinThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Mianserin.Approved, Investigational
MibefradilThe metabolism of Ethosuximide can be decreased when combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe metabolism of Ethosuximide can be decreased when combined with Miconazole.Approved, Investigational, Vet Approved
MicronomicinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Micronomicin.Experimental
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Ethosuximide.Approved, Illicit
MidomafetamineMidomafetamine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Illicit, Investigational
MifepristoneThe serum concentration of Ethosuximide can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Milnacipran.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Minaprine.Approved
Mineral oilThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Ethosuximide.Approved, Vet Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.Approved, Investigational
MirtazapineEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Ethosuximide can be decreased when it is combined with Mitotane.Approved
MivacuriumEthosuximide may increase the neuromuscular blocking activities of Mivacurium.Approved
MK-212The risk or severity of adverse effects can be increased when Ethosuximide is combined with MK-212.Investigational
MMDAMMDA can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Moclobemide.Approved, Investigational
ModafinilThe serum concentration of Ethosuximide can be decreased when it is combined with Modafinil.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Molindone.Approved
MoperoneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Moperone.Experimental
MoricizineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Moricizine.Approved, Investigational, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Ethosuximide.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Mosapramine.Experimental
MosaprideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Mosapride.Investigational
MRK-409The risk or severity of adverse effects can be increased when Ethosuximide is combined with MRK-409.Experimental
N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.Approved, Investigational
NafcillinThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Nafcillin.Approved, Investigational
NaftidrofurylThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Naftidrofuryl.Experimental
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Ethosuximide.Approved
NaloxoneThe metabolism of Ethosuximide can be decreased when combined with Naloxone.Approved, Vet Approved
NaluzotanThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Naluzotan.Investigational
NaratriptanThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Naratriptan.Approved, Investigational
NaronaprideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Naronapride.Investigational
NeamineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Neamine.Experimental
NefazodoneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Nefazodone.Approved, Withdrawn
NefiracetamThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Nefiracetam.Investigational
NelfinavirThe metabolism of Ethosuximide can be decreased when combined with Nelfinavir.Approved
NeocitrullamonThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Neocitrullamon.Experimental
NeomycinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Neomycin.Approved, Vet Approved
NeosaxitoxinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Neosaxitoxin.Investigational
NetilmicinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Netilmicin.Approved, Investigational
NetupitantThe serum concentration of Ethosuximide can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Ethosuximide can be increased when combined with Nevirapine.Approved
NialamideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Nialamide.Withdrawn
NiaprazineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Niaprazine.Experimental
NicardipineThe risk or severity of hypotension can be increased when Nicardipine is combined with Ethosuximide.Approved, Investigational
NicergolineThe risk or severity of hypotension can be increased when Nicergoline is combined with Ethosuximide.Approved, Investigational
NiguldipineThe risk or severity of hypotension can be increased when Niguldipine is combined with Ethosuximide.Experimental
NilotinibThe metabolism of Ethosuximide can be decreased when combined with Nilotinib.Approved, Investigational
NisoxetineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Nisoxetine.Experimental
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Ethosuximide.Approved
NitroprussideEthosuximide may increase the hypotensive activities of Nitroprusside.Approved, Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Ethosuximide.Approved, Vet Approved
NomifensineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Nomifensine.Withdrawn
NordazepamThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Nordazepam.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of hypotension can be increased when Nortriptyline is combined with Ethosuximide.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Octamoxin.Withdrawn
OlanzapineThe risk or severity of hypotension can be increased when Olanzapine is combined with Ethosuximide.Approved, Investigational
OlaparibThe metabolism of Ethosuximide can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Olopatadine.Approved
OmoconazoleThe therapeutic efficacy of Omoconazole can be increased when used in combination with Ethosuximide.Experimental
OndansetronThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Ondansetron.Approved
OpipramolThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Opipramol.Investigational
OpiumThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Opium.Approved, Illicit
OrlistatOrlistat can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
OrphenadrineEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OrvepitantThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Orvepitant.Investigational
OsanetantThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Ethosuximide can be increased when it is combined with Osimertinib.Approved
OxaflozaneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Oxaflozane.Experimental
OxaprotilineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Oxaprotiline.Experimental
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Ethosuximide.Approved
OxcarbazepineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Oxcarbazepine.Approved
OxiconazoleThe therapeutic efficacy of Oxiconazole can be increased when used in combination with Ethosuximide.Approved
OxiracetamThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Oxiracetam.Experimental
OxitriptanThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Oxitriptan.Approved, Investigational, Nutraceutical
OxprenololThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Oxprenolol.Approved
OxtriphyllineEthosuximide may increase the excretion rate of Oxtriphylline which could result in a lower serum level and potentially a reduction in efficacy.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ethosuximide.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ethosuximide.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Oxypertine.Experimental
OxyphenisatinThe therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Ethosuximide.Investigational, Withdrawn
OxytetracyclineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Oxytetracycline.Approved, Investigational, Vet Approved
PalbociclibThe serum concentration of Ethosuximide can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe risk or severity of hypotension can be increased when Paliperidone is combined with Ethosuximide.Approved
PalonosetronThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Palonosetron.Approved, Investigational
PancuroniumEthosuximide may increase the neuromuscular blocking activities of Pancuronium.Approved
ParaldehydeEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParamethadioneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Paramethadione.Approved
PargylineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Pargyline.Approved
ParomomycinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Paromomycin.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Paroxetine.Approved, Investigational
PeldesineEthosuximide may increase the excretion rate of Peldesine which could result in a lower serum level and potentially a reduction in efficacy.Experimental, Investigational
PemetrexedEthosuximide may increase the excretion rate of Pemetrexed which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
PenbutololThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Penbutolol.Approved, Investigational
PenciclovirEthosuximide may increase the excretion rate of Penciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved
PenfluridolThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Penfluridol.Experimental
PenimepicyclineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Penimepicycline.Experimental
PentaerithritylThe therapeutic efficacy of Pentaerithrityl can be decreased when used in combination with Ethosuximide.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ethosuximide.Approved, Vet Approved
PentifyllineEthosuximide may increase the excretion rate of Pentifylline which could result in a lower serum level and potentially a reduction in efficacy.Experimental
PentobarbitalThe metabolism of Ethosuximide can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PentoxifyllineEthosuximide may increase the excretion rate of Pentoxifylline which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.Approved
PerazineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Perazine.Approved, Investigational
PergolideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerospironeThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Ethosuximide.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Ethosuximide.Approved
PhenacemideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Phenacemide.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Phenazocine.Experimental
PhencyclidineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Phencyclidine.Illicit
PhenelzineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Phenelzine.Approved
PhenethylamineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Phenethylamine.Experimental
PheneturideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Pheneturide.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Phenibut.Experimental
PheniprazineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Pheniprazine.Withdrawn
PhenobarbitalThe metabolism of Ethosuximide can be increased when combined with Phenobarbital.Approved, Investigational
PhenolphthaleinThe therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Ethosuximide.Approved, Withdrawn
PhenoperidineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Phenoperidine.Experimental
PhenoxybenzamineThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Ethosuximide.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Phenoxypropazine.Withdrawn
PhenprobamateThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Phenprobamate.Experimental
PhensuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Phensuximide.Approved
PhenterminePhentermine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Illicit
PhentolamineThe risk or severity of hypotension can be increased when Phentolamine is combined with Ethosuximide.Approved
PiclozotanThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Piclozotan.Investigational
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Ethosuximide.Approved
PimavanserinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Pimavanserin.Approved, Investigational
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Ethosuximide.Approved
PinazepamThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Pinazepam.Experimental
PindololThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Pindolol.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Pipamperone.Approved, Investigational
PipecuroniumEthosuximide may increase the neuromuscular blocking activities of Pipecuronium.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Piritramide.Approved, Investigational
PirlimycinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Pirlimycin.Vet Approved
PirlindoleThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Pirlindole.Approved
PitolisantThe serum concentration of Ethosuximide can be decreased when it is combined with Pitolisant.Approved, Investigational
PivagabineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Pivagabine.Investigational
PivhydrazineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Pivhydrazine.Withdrawn
PizotifenThe risk or severity of hypotension can be increased when Pizotifen is combined with Ethosuximide.Approved
Plantago seedThe therapeutic efficacy of Plantago seed can be decreased when used in combination with Ethosuximide.Approved, Investigational
PlazomicinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Plazomicin.Approved, Investigational
PlecanatideThe therapeutic efficacy of Plecanatide can be decreased when used in combination with Ethosuximide.Approved, Investigational
PolycarbophilThe therapeutic efficacy of Polycarbophil can be decreased when used in combination with Ethosuximide.Approved
Polyethylene glycolThe therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Ethosuximide.Approved, Vet Approved
Polymyxin B SulfateThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Polymyxin B Sulfate.Approved, Vet Approved
PomalidomideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Ethosuximide can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
Potassium acetateThe therapeutic efficacy of Potassium acetate can be decreased when used in combination with Ethosuximide.Approved, Investigational
PramipexoleEthosuximide may increase the sedative activities of Pramipexole.Approved, Investigational
PrazepamThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Prazepam.Approved, Illicit
PrazosinThe risk or severity of hypotension can be increased when Prazosin is combined with Ethosuximide.Approved
PregabalinThe therapeutic efficacy of Ethosuximide can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PridinolThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Pridinol.Experimental
PrimidoneThe metabolism of Ethosuximide can be increased when combined with Primidone.Approved, Vet Approved
ProcainamideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Procarbazine.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ethosuximide.Approved, Vet Approved
ProgabideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Progabide.Approved, Investigational
PromazineThe risk or severity of hypotension can be increased when Promazine is combined with Ethosuximide.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Promethazine.Approved, Investigational
PropanididThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Propanidid.Experimental
PropentofyllineEthosuximide may increase the excretion rate of Propentofylline which could result in a lower serum level and potentially a reduction in efficacy.Investigational
PropericiazineThe risk or severity of hypotension can be increased when Propericiazine is combined with Ethosuximide.Approved, Investigational
PropiomazineThe risk or severity of hypotension can be increased when Propiomazine is combined with Ethosuximide.Approved
PropiopromazineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Propiopromazine.Vet Approved
PropiverineThe risk or severity of hypotension can be increased when Propiverine is combined with Ethosuximide.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Ethosuximide.Approved, Investigational, Vet Approved
ProthipendylThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Ethosuximide.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Proxibarbal.Experimental
ProxyphyllineEthosuximide may increase the excretion rate of Proxyphylline which could result in a lower serum level and potentially a reduction in efficacy.Experimental
PrucaloprideThe therapeutic efficacy of Prucalopride can be decreased when used in combination with Ethosuximide.Approved
PRX-08066The risk or severity of adverse effects can be increased when Ethosuximide is combined with PRX-08066.Investigational
PseudoephedrinePseudoephedrine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PsilocybineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Psilocybine.Investigational
PuromycinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Puromycin.Experimental
PyrantelThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Pyrantel.Approved, Vet Approved
PyrithyldioneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Pyrithyldione.Experimental
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Ethosuximide.Approved, Illicit
QuetiapineThe risk or severity of hypotension can be increased when Quetiapine is combined with Ethosuximide.Approved
QuinidineThe risk or severity of hypotension can be increased when Quinidine is combined with Ethosuximide.Approved, Investigational
QuinineThe metabolism of Ethosuximide can be increased when combined with Quinine.Approved
QuinupramineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Quinupramine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Ramelteon.Approved, Investigational
RamosetronThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Ramosetron.Approved, Investigational
RapacuroniumEthosuximide may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RasagilineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Rasagiline.Approved
RavuconazoleThe therapeutic efficacy of Ravuconazole can be increased when used in combination with Ethosuximide.Investigational
ReboxetineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Reboxetine.Approved, Investigational
RemacemideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Remacemide.Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ethosuximide.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Remoxipride.Approved, Withdrawn
RenzaprideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Renzapride.Investigational
RepinotanThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Repinotan.Investigational
ReposalThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Reposal.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Ethosuximide.Approved, Investigational
RibostamycinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Ribostamycin.Approved, Investigational
RifampicinThe metabolism of Ethosuximide can be increased when combined with Rifampicin.Approved
RifamycinThe metabolism of Ethosuximide can be increased when combined with Rifamycin.Investigational
RifapentineThe metabolism of Ethosuximide can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe metabolism of Ethosuximide can be increased when combined with Rifaximin.Approved, Investigational
RiluzoleThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Riluzole.Approved, Investigational
RimexoloneThe metabolism of Ethosuximide can be increased when combined with Rimexolone.Approved
RisperidoneThe risk or severity of hypotension can be increased when Risperidone is combined with Ethosuximide.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Ritanserin.Investigational
RitobegronRitobegron can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
RitonavirThe metabolism of Ethosuximide can be decreased when combined with Ritonavir.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Rizatriptan.Approved
RocuroniumEthosuximide may increase the neuromuscular blocking activities of Rocuronium.Approved
RolipramThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Rolipram.Investigational
RolitetracyclineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Rolitetracycline.Approved
RomifidineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Romifidine.Vet Approved
RopiniroleEthosuximide may increase the sedative activities of Ropinirole.Approved, Investigational
RotigotineEthosuximide may increase the sedative activities of Rotigotine.Approved
RP-5063The risk or severity of adverse effects can be increased when Ethosuximide is combined with RP-5063.Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Ethosuximide.Approved
SafinamideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Safinamide.Approved, Investigational
SafrazineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Safrazine.Withdrawn
SaquinavirThe metabolism of Ethosuximide can be decreased when combined with Saquinavir.Approved, Investigational
SaredutantThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Saredutant.Investigational
SarilumabThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Sarilumab.Approved, Investigational
SarpogrelateThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Sarpogrelate.Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Scopolamine.Approved, Investigational
SecobarbitalThe metabolism of Ethosuximide can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Selegiline.Approved, Investigational, Vet Approved
SennosidesThe therapeutic efficacy of Sennosides can be decreased when used in combination with Ethosuximide.Approved
SerotoninThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Serotonin.Investigational, Nutraceutical
SertaconazoleThe therapeutic efficacy of Sertaconazole can be increased when used in combination with Ethosuximide.Approved, Investigational
SertindoleThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Ethosuximide.Approved, Vet Approved
SibutramineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Sibutramine.Approved, Illicit, Investigational, Withdrawn
SilodosinThe risk or severity of hypotension can be increased when Silodosin is combined with Ethosuximide.Approved
SiltuximabThe serum concentration of Ethosuximide can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Ethosuximide can be increased when it is combined with Simeprevir.Approved
SisomicinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Sisomicin.Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.Approved
Sodium phosphate, monobasicThe therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Ethosuximide.Approved
Sodium sulfateThe therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Ethosuximide.Approved, Vet Approved
Sodium tartrateThe therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Ethosuximide.Approved
SorbitolThe therapeutic efficacy of Sorbitol can be decreased when used in combination with Ethosuximide.Approved
St. John's WortThe serum concentration of Ethosuximide can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Ethosuximide can be increased when it is combined with Stiripentol.Approved
StreptomycinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Streptomycin.Approved, Vet Approved
StyramateThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Styramate.Experimental
SuccinylcholineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Succinylcholine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ethosuximide.Approved, Investigational
SulconazoleThe therapeutic efficacy of Sulconazole can be increased when used in combination with Ethosuximide.Approved
SulpirideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Sulpiride.Approved, Investigational
SulthiameThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Sulthiame.Experimental
SultoprideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Sumatriptan.Approved, Investigational
SuvorexantEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TalbutalThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Talbutal.Approved, Illicit
TalopramThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Talopram.Experimental
TamsulosinThe risk or severity of hypotension can be increased when Tamsulosin is combined with Ethosuximide.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Tasimelteon.Approved, Investigational
TD-8954The risk or severity of adverse effects can be increased when Ethosuximide is combined with TD-8954.Investigational
Tedizolid phosphateThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Tedizolid phosphate.Approved
TegaserodThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Tegaserod.Approved, Investigational, Withdrawn
TelaprevirThe metabolism of Ethosuximide can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Ethosuximide can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Ethosuximide.Approved, Investigational
TerazosinThe risk or severity of hypotension can be increased when Terazosin is combined with Ethosuximide.Approved
TerconazoleThe therapeutic efficacy of Terconazole can be increased when used in combination with Ethosuximide.Approved
TetracyclineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Tetracycline.Approved, Vet Approved
TetrahydrocannabivarinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Tetrahydrocannabivarin.Investigational
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Tetrahydropalmatine.Investigational
TetrazepamThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Tetrazepam.Experimental
TetrodotoxinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Tetrodotoxin.Investigational
ThalidomideEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheobromineEthosuximide may increase the excretion rate of Theobromine which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
TheodrenalineEthosuximide may increase the excretion rate of Theodrenaline which could result in a lower serum level and potentially a reduction in efficacy.Investigational
ThiamylalThe metabolism of Ethosuximide can be increased when combined with Thiamylal.Approved, Vet Approved
ThiazinamThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Thiazinam.Experimental
ThiethylperazineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Thiethylperazine.Withdrawn
ThiocolchicosideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Thiocolchicoside.Approved, Investigational
ThiopentalThe metabolism of Ethosuximide can be increased when combined with Thiopental.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Thiopropazate.Experimental
ThioproperazineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Ethosuximide.Approved
ThioridazineThe risk or severity of hypotension can be increased when Thioridazine is combined with Ethosuximide.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Ethosuximide.Approved
TiagabineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Tiagabine.Approved, Investigational
TianeptineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Tianeptine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Tiapride.Approved, Investigational
TigecyclineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Tigecycline.Approved
TiletamineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Tilidine.Experimental
TioconazoleThe therapeutic efficacy of Tioconazole can be increased when used in combination with Ethosuximide.Approved
TipranavirThe metabolism of Ethosuximide can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Tizanidine.Approved, Investigational
TobramycinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Tobramycin.Approved, Investigational
TocilizumabThe serum concentration of Ethosuximide can be decreased when it is combined with Tocilizumab.Approved
TofisopamThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Tofisopam.Approved
TolazolineThe risk or severity of hypotension can be increased when Tolazoline is combined with Ethosuximide.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Ethosuximide.Approved, Withdrawn
ToloxatoneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Toloxatone.Approved
TolperisoneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Tolperisone.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Ethosuximide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Ethosuximide.Approved, Investigational
TramiprosateThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Tramiprosate.Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Tranylcypromine.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Ethosuximide.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Trichloroethylene.Approved
TriclofosThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Triclofos.Withdrawn
TrifluoperazineThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Ethosuximide.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Triflupromazine.Approved, Vet Approved
TrimazosinThe risk or severity of hypotension can be increased when Trimazosin is combined with Ethosuximide.Experimental
TrimethadioneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Trimethadione.Approved
TrimipramineThe risk or severity of hypotension can be increased when Trimipramine is combined with Ethosuximide.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Ethosuximide.Approved
TroleandomycinThe metabolism of Ethosuximide can be decreased when combined with Troleandomycin.Approved
TropisetronThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Tropisetron.Approved, Investigational
TubocurarineEthosuximide may increase the neuromuscular blocking activities of Tubocurarine.Approved
UrapidilThe risk or severity of hypotension can be increased when Urapidil is combined with Ethosuximide.Investigational
Uric AcidEthosuximide may increase the excretion rate of Uric Acid which could result in a lower serum level and potentially a reduction in efficacy.Experimental, Investigational
VabicaserinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Vabicaserin.Investigational
ValaciclovirEthosuximide may increase the excretion rate of Valaciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
ValerianThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Valerian.Approved, Experimental, Investigational
ValganciclovirEthosuximide may increase the excretion rate of Valganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
ValnoctamideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Valnoctamide.Investigational
ValomaciclovirEthosuximide may increase the excretion rate of Valomaciclovir which could result in a lower serum level and potentially a reduction in efficacy.Investigational
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Ethosuximide.Approved, Investigational
ValpromideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Valpromide.Experimental
VancomycinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Vancomycin.Approved
VecuroniumEthosuximide may increase the neuromuscular blocking activities of Vecuronium.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Ethosuximide.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Veralipride.Experimental
VerapamilThe risk or severity of hypotension can be increased when Verapamil is combined with Ethosuximide.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Vilazodone.Approved
ViloxazineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Viloxazine.Approved, Investigational, Withdrawn
VinbarbitalThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Vinbarbital.Experimental
VinpocetineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Vinpocetine.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Vinyl ether.Experimental
VinylbitalThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Vinylbital.Experimental
VoriconazoleThe metabolism of Ethosuximide can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Vortioxetine.Approved, Investigational
WortmanninThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Wortmannin.Experimental
XanthineEthosuximide may increase the excretion rate of Xanthine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
XP19986The risk or severity of adverse effects can be increased when Ethosuximide is combined with XP19986.Investigational
XylazineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Xylazine.Vet Approved
YKP-1358The risk or severity of adverse effects can be increased when Ethosuximide is combined with YKP-1358.Investigational
YohimbineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Yohimbine.Approved, Investigational, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Ethosuximide.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of hypotension can be increased when Ziprasidone is combined with Ethosuximide.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Zolmitriptan.Approved, Investigational
ZolpidemEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Ethosuximide.Approved
ZotepineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Zotepine.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Ethosuximide.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take with food.

References

Synthesis Reference

Miller, C.A. and Long, L.M.; U.S. Patent 2,993,835; July 25,1961; assigned to Parke, Davis and Company.

General References
  1. Patsalos PN: Properties of antiepileptic drugs in the treatment of idiopathic generalized epilepsies. Epilepsia. 2005;46 Suppl 9:140-8. [PubMed:16302888]
  2. Coulter DA, Huguenard JR, Prince DA: Specific petit mal anticonvulsants reduce calcium currents in thalamic neurons. Neurosci Lett. 1989 Mar 13;98(1):74-8. [PubMed:2710401]
  3. Coulter DA, Huguenard JR, Prince DA: Characterization of ethosuximide reduction of low-threshold calcium current in thalamic neurons. Ann Neurol. 1989 Jun;25(6):582-93. [PubMed:2545161]
  4. Coulter DA, Huguenard JR, Prince DA: Differential effects of petit mal anticonvulsants and convulsants on thalamic neurones: calcium current reduction. Br J Pharmacol. 1990 Aug;100(4):800-6. [PubMed:2169941]
  5. Kostyuk PG, Molokanova EA, Pronchuk NF, Savchenko AN, Verkhratsky AN: Different action of ethosuximide on low- and high-threshold calcium currents in rat sensory neurons. Neuroscience. 1992 Dec;51(4):755-8. [PubMed:1336826]
External Links
Human Metabolome Database
HMDB0014731
KEGG Drug
D00539
KEGG Compound
C07505
PubChem Compound
3291
PubChem Substance
46507617
ChemSpider
3175
BindingDB
50240424
ChEBI
4887
ChEMBL
CHEMBL696
Therapeutic Targets Database
DAP000526
PharmGKB
PA449533
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Ethosuximide
ATC Codes
N03AD51 — Ethosuximide, combinationsN03AD01 — Ethosuximide
AHFS Codes
  • 28:12.20 — Succinimides
FDA label
Download (174 KB)
MSDS
Download (73.5 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1, 2TerminatedPreventionMigrainous Headache1
2CompletedSupportive CareCancers / Peripheral Neuropathy1
2CompletedTreatmentNeuropathic Traumatic Pain / Pain NRS ≥ 41
2RecruitingTreatmentIrritable Bowel Syndrome (IBS)1
2TerminatedTreatmentComplex Regional Pain Syndromes (CRPS)1
3CompletedTreatmentChildhood Absence Epilepsy / Epilepsies / Petit Mal Epilepsy / Seizures1
4RecruitingTreatmentEpilepsies1

Pharmacoeconomics

Manufacturers
  • Banner pharmacaps inc
  • Convenant pharma inc
  • Parke davis div warner lambert co
  • Mikart inc
  • Pharmaceutical assoc inc div beach products
  • Teva pharmaceuticals usa
  • Parke davis pharmaceutical research div warner lambert co
Packagers
  • Barr Pharmaceuticals
  • Catalent Pharma Solutions
  • Mikart Inc.
  • Pfizer Inc.
  • Pharmaceutical Association
  • Pliva Inc.
  • Swiss Caps Ag
  • Teva Pharmaceutical Industries Ltd.
  • Versapharm Inc.
Dosage forms
FormRouteStrength
CapsuleOral250 1/1
CapsuleOral250 mg/1
Capsule, liquid filledOral250 mg/1
SolutionOral250 mg/5mL
CapsuleOral250 mg
SyrupOral250 mg
Prices
Unit descriptionCostUnit
Ethosuximide 250 mg/5ml Solution 474ml Bottle84.2USD bottle
Ethosuximide 250 mg capsule1.26USD capsule
Zarontin 250 mg capsule1.16USD capsule
Zarontin 250 mg/5ml Solution0.34USD ml
Zarontin 50 mg/ml Syrup0.07USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)64.5 °CPhysProp
water solubility39.2 g/LNot Available
logP0.38ATKINSON,HC & BERG,EJ (1988)
Predicted Properties
PropertyValueSource
Water Solubility101.0 mg/mLALOGPS
logP0.1ALOGPS
logP0.55ChemAxon
logS-0.15ALOGPS
pKa (Strongest Acidic)10.73ChemAxon
pKa (Strongest Basic)-6.6ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area46.17 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity35.96 m3·mol-1ChemAxon
Polarizability14.45 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9983
Caco-2 permeable+0.5262
P-glycoprotein substrateNon-substrate0.5832
P-glycoprotein inhibitor INon-inhibitor0.7859
P-glycoprotein inhibitor IINon-inhibitor0.9923
Renal organic cation transporterNon-inhibitor0.8867
CYP450 2C9 substrateNon-substrate0.8492
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateSubstrate0.5108
CYP450 1A2 substrateNon-inhibitor0.9242
CYP450 2C9 inhibitorNon-inhibitor0.9072
CYP450 2D6 inhibitorNon-inhibitor0.9232
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9276
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.93
Ames testNon AMES toxic0.858
CarcinogenicityNon-carcinogens0.8526
BiodegradationNot ready biodegradable0.9299
Rat acute toxicity1.9213 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9939
hERG inhibition (predictor II)Non-inhibitor0.9795
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (8.34 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-08mi-9400000000-44583cdc88d3203a4e84
GC-MS Spectrum - CI-BGC-MSsplash10-0006-1900000000-1c27ada66f7846f9d155
GC-MS Spectrum - CI-BGC-MSsplash10-0006-2900000000-19e57defe9ded4ed42b4
Mass Spectrum (Electron Ionization)MSsplash10-08mi-9300000000-3d87944377ee1f85803d
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as pyrrolidine-2-ones. These are pyrrolidines which bear a C=O group at position 2 of the pyrrolidine ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyrrolidines
Sub Class
Pyrrolidones
Direct Parent
Pyrrolidine-2-ones
Alternative Parents
N-unsubstituted carboxylic acid imides / Dicarboximides / Lactams / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
2-pyrrolidone / Carboxylic acid imide / Dicarboximide / Carboxylic acid imide, n-unsubstituted / Lactam / Carboxylic acid derivative / Azacycle / Carbonyl group / Organooxygen compound / Organonitrogen compound
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
pyrrolidinone, dicarboximide (CHEBI:4887)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Scaffold protein binding
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1G
Uniprot ID
O43497
Uniprot Name
Voltage-dependent T-type calcium channel subunit alpha-1G
Molecular Weight
262468.62 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Gomora JC, Daud AN, Weiergraber M, Perez-Reyes E: Block of cloned human T-type calcium channels by succinimide antiepileptic drugs. Mol Pharmacol. 2001 Nov;60(5):1121-32. [PubMed:11641441]
  3. Wang G, Thompson SM: Maladaptive homeostatic plasticity in a rodent model of central pain syndrome: thalamic hyperexcitability after spinothalamic tract lesions. J Neurosci. 2008 Nov 12;28(46):11959-69. doi: 10.1523/JNEUROSCI.3296-08.2008. [PubMed:19005061]
  4. Matthews EA, Dickenson AH: Effects of ethosuximide, a T-type Ca(2+) channel blocker, on dorsal horn neuronal responses in rats. Eur J Pharmacol. 2001 Mar;415(2-3):141-9. [PubMed:11274992]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Monooxygenase activity
Specific Function
Exhibits low testosterone 6-beta-hydroxylase activity.
Gene Name
CYP3A43
Uniprot ID
Q9HB55
Uniprot Name
Cytochrome P450 3A43
Molecular Weight
57669.21 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 09:42